 |
|
| Systematic (IUPAC) name | |
|---|---|
| 4-[(3-Chloro-4-methoxybenzyl)amino]-2-
[2-(hydroxymethyl)-1-pyrrolidinyl]-N- (2-pyrimidinylmethyl)-5-pyrimidinecarboxamide |
|
| Identifiers | |
| CAS number | 330784-47-9 |
| ATC code | none |
| PubChem | 9869929 |
| ChemSpider | 8045620 |
| Chemical data | |
| Formula | C23H26ClN7O3 |
| Mol. mass | 483.951 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Avanafil (dubbed as "Son of Viagra"[1]) is a PDE5 inhibitor being developed for erectile dysfunction. Avanafil currently has no trademarked term associated with it but it being developed by Vivus Inc. It acts by inhibiting a specific phosphodiesterase type 5 enzyme which if found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil.
Contents |
See also
References
- ^ "SCIENTISTS have made a “son of Viagra” pill that works extra-fast." (in English). The Sun. October 28, 2008. http://www.thesun.co.uk/sol/homepage/news/article1863213.ece. Retrieved 2008-10-30.
Further reading
- Faster-Working Erectile Dysfunction Drug? cbsnews.com Nov 25th 2009
External links
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
